When was Soligenix founded?

Soligenix was founded in 1987 and raised its 1st funding round 22 years after it was founded.

Where is Soligenix located?

Soligenix is headquartered in Princeton, United States. It is registered at 29 EMMONS DRIVE, SUITE B-10 PRINCETON, NJ.

How many employees does Soligenix have?

As of Aug 31, 2026, the latest employee count at Soligenix is 25.

Is Soligenix a funded company?

Soligenix is a funded company, having raised an undisclosed amount across 24 funding rounds to date. The company's 1st funding round was a $***** Post IPO round, raised on Jan 20, 2009.

When was the latest funding round of Soligenix?

Soligenix's latest funding was a $***** Grant (prize money) round on Sep 12, 2022, with participation from 1 investor.

What is the annual revenue of Soligenix?

Annual revenue of Soligenix is less than $1M as on Dec 31, 2024

Where does Soligenix rank among its competitors?

Soligenix ranks 74th amongst 314 active competitors, of which 83 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was BridgeBio, which secured $200M in Apr, 2024.

Who are the top competitors of Soligenix?

Soligenix's top competitors include BridgeBio, Alnylam and PTC Therapeutics. Among them, BridgeBio secured the most recent funding round in April, 2024.

Soligenix - 2026 Company Profile, Funding, Competitors & Financials

Soligenix is a public company based in Princeton (United States), founded in 1987. It operates as a Developer of small molecule therapeutics for rare disease therapies. Soligenix has raised an undisclosed amount in funding. The company has 314 active competitors, including 83 funded and 108 that have exited. Its top competitors include companies like BridgeBio, Alnylam and PTC Therapeutics.

Company Details

Developer of small molecule therapeutics for rare disease therapies. It offers HyBryte which is a photodynamic topical therapy using a hypericin ointment for the treatment of cutaneous T-cell lymphoma, SGX302 is a topical formulation with photosensitizing activity for the treatment of psoriasis, SGX945 for the treatment of aphthous ulcers of Behçet’s Disease, and SGX942 for the treatment of oral mucositis in head and neck cancer patients.

Website: www.soligenix.com
Social
Registered Address: 29 EMMONS DRIVE, SUITE B-10 PRINCETON, NJ

Key Metrics

Founded Year

1987

Location

Princeton, United States

Stage

Public

Latest Funding Round

Grant (prize money), Sep 12, 2022, $*****

Investors

Third Security & 15 more

Ranked

74^th among 314 active competitors

Annual Revenue

$0 - $1M as on Dec 31, 2024

Employee Count

25 as on Aug 31, 2026

Similar Companies

BridgeBio & 349 more

Exit Details

Public

View Soligenix's full profile

Soligenix is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
DOR BIOPHARMA INC CIN: 812796 , United States, Active		$1M - $5M (As on Mar 20, 2009)	-	-
Soligenix, Inc. CIN: 812796 , United States, Active	Jan 15, 1987	$0 - $1M (As on Dec 31, 2024)	-	-
SOLIGENIX, INC CIN: 41-1505029 , United States, Active	Dec 31, 1986	-	15 (As on Dec 31, 2022)	-

Soligenix got listed on Jun 15, 1987.

Click here to take a look at Soligenix's IPO in detail

Soligenix has raised funding over 24 rounds. Its first funding round was on Jan 20, 2009. Its latest funding round was a Grant (prize money) round on Sep 12, 2022 for $*****. 1 investor participated in its latest round. Soligenix has 16 institutional investors.

Here is the list of recent funding rounds of Soligenix:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 12, 2022	5453831	Grant (prize money)	6972452	8606916	2506550	8279362
Jun 09, 2021	1514150	Grant (prize money)	3969754	6785405	8876640	New Jersey Economic Development Authority
Dec 28, 2020	8476930	Grant (prize money)	9002554	3841657	7979617	NIH

Access funding benchmarks and valuations. Sign up today!

View details of Soligenix's funding rounds and investors

Soligenix's employee count trend

Soligenix has 25 employees as of Aug 26. Here is Soligenix's employee count trend over the years:

Uncover Soligenix's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Soligenix include BridgeBio, Alnylam and PTC Therapeutics. Here is the list of Top 10 competitors of Soligenix, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	BridgeBio 2015, Palo Alto (United States), Public	Developer of therapeutics for the treatment of genetic diseases	$434M	Viking Global Investors, KKR & 20 others	81/100
2nd	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Atlas Venture & 13 others	79/100
3rd	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 28 others	77/100
4th	Alexion 1992, Zurich (Switzerland), Acquired	Developer of therapies for patients with devastating and rare diseases	$133M	Allen & Company, Invesco & 9 others	74/100
5th	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	73/100
6th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Nextech Invest, Third Rock Ventures & 20 others	71/100
7th	Bluebird Bio 1992, Cambridge (United States), Acquired	Developer of gene therapies for severe genetic and rare diseases	$136M	TVM Capital, Forbion & 10 others	71/100
8th	Agios Pharmaceuticals 2008, Cambridge (United States), Public	Developer of therapeutics in the field of cancer metabolism and rare genetic disorders of metabolism	$120M	Arch Venture Partners, Flagship Pioneering ... & 6 others	70/100
9th	Rhythm Pharmaceuticals 2010, Boston (United States), Public	Developer of peptide therapeutics for the treatment of rare genetic deficiencies	$84M	Pfizer Venture Investments, Third Rock Ventures ... & 9 others	70/100
10th	Regenxbio 2008, Rockville (United States), Public	Developer of AAV Gene Therapy for rare genetic diseases	$108M	Brookside Capital, Venrock & 15 others	67/100
74th	Soligenix 1987, Princeton (United States), Public	Developer of small molecule therapeutics for rare disease therapies	-	Third Security, Pontifax & 14 others	53/100